Stryker (SYK) Q3 2026 Earnings Report

The call was cautiously constructive but balanced. Stryker reported solid sales growth, adjusted EPS growth, margin expansion, strong cash generation, healthy capital demand, product momentum and a broad innovation and M&A pipeline. However, these positives were offset by a meaningful hip and knee market slowdown, weaker-than-expected commercial execution, Peripheral Vascular supply constraints and reduced full-year guidance. Management expressed confidence in the long-term outlook but acknowledged continued near-term uncertainty.

Stryker’s updated guidance anticipates a similar overall organic growth rate for the company in Q4 as achieved in Q3, when organic sales growth was 7.7%, assuming a continuation of the procedure environment observed this quarter and continued strong capital demand; the company expects full year organic net sales growth of 6.5% to 7% and adjusted net earnings per share of $14.80 to $14.90, adjusted other income and expense of approximately $400 million, and a full year effective tax rate in the range of 15.5% to 16%. For Q4, Stryker expects strong growth for Trauma and Extremities, Medical to perform well, Instruments to have strong performances, and Peripheral Vascular to be a little bit better underlying; for 2027, while it will not provide formal guidance until early next year, it expects to deliver growth at the high end of our markets.